Sino Biopharmaceutical Limited
SBHMY · OTC
6/30/2025 | 3/31/2025 | 12/31/2024 | 9/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.00 | 0.02 | 0.00 | -0.79 |
| FCF Yield | 0.00% | 0.00% | 0.00% | 0.00% |
| EV / EBITDA | 26.97 | 27.05 | 48.59 | 44.60 |
| Quality | ||||
| ROIC | 2.67% | 2.67% | 2.72% | 2.72% |
| Gross Margin | 82.47% | 82.47% | 80.82% | 80.82% |
| Cash Conversion Ratio | – | – | – | – |
| Growth | ||||
| Revenue 3-Year CAGR | 5.51% | 1.71% | 1.38% | 3.31% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | -100.00% |
| Safety | ||||
| Net Debt / EBITDA | -3.98 | -3.98 | 0.20 | 0.20 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.73 | 0.73 | 0.52 | 0.52 |
| Cash Conversion Cycle | 41.66 | 41.66 | 132.72 | 132.09 |